The IPKat

NOVEMBER 4, 2023

Glyn Moody says about the book: “Ed Sheeran and Dua Lipa get sued for alleged plagiarism and the majority of creators see pennies for their work, while the revenues of the record labels are exploding. This is a review of Walled Culture: How Big Content Uses Technology and the Law to Lock Down Culture and Keep Creators Poor by Glyn Moody.

Copying 85

Copying Copyright Music Plagiarism 85

The IPKat

NOVEMBER 14, 2022

It is obviously not easy to summarise three full days of very intensive work (and many coffee breaks) and the reports of dozens of experts who effectively shared their knowledge with the participants, in an atmosphere open to debate and discussion.

IP 76

IP Marketing Marketing Confidentiality 76

The IPKat

SEPTEMBER 30, 2022

Marco Spolidoro gave a lecture on the very topical subject of NFTs (which this blog recently covered here ). Rosaria Romano underlined how ‘copyright’ has become over the years a tool for providing a legal framework to works that are all but homogeneous but that still present common characteristics.

Reporting 91

Reporting Copyright Intellectual Property Moral Rights 91

The IPKat

AUGUST 24, 2021

Here is what Alexander has to say: It was a delight to learn last year that Simon Stokes, copyright solicitor at Blake Morgan in London, was working on a third edition of his eminently useful Art and Copyright. The new edition of Stokes’s classic work makes a welcome addition to any library.

Art 98

Art Copyright Editing Publishing 98

Kluwer Copyright Blog

JUNE 1, 2023

Our members are leading European scholars and academics from various European countries seeking to share their views with the public and decision makers and to pursue the overall public interest on all topics concerning the authors’ rights, neighboring rights, and related matters.

Copyright Law 111

Copyright Law Copyright Law Art 111

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., With respect to Q.I.16, With respect to Q.I.20,

Litigation 52

Litigation Settlement Patent Marketing 52